摘要
目的:观察瑞舒伐他汀治疗老年人下肢动脉粥样硬化的临床效果,为他汀类药物在抗老年人下肢动脉样硬化中的应用提供临床依据。方法:选取下肢动脉粥样硬化疾病患者90例(年龄≥60岁),随机分为辛伐他汀组和瑞舒伐他汀组(每组各45例),在其基础疾病常规治疗的同时分别给予辛伐他汀40mg和瑞舒伐他汀10mg治疗。于治疗开始时和32周结束时分别测定2组患者总胆固醇(TC)、低密度脂蛋白(LDL-C)和超敏C反应蛋白(hs-CRP)等生化指标,同时对2组患者下肢动脉内膜厚度、硬化强度、斑块和动脉狭窄程度进行评分比较。结果:治疗32周时,2组患者TC、LDL-C和hs-CRP水平较治疗前下降(P<0.05),治疗32周时瑞舒伐他汀组患者TC、LDL-C和hs-CRP水平均低于辛伐他汀组(P<0.05)。治疗32周时,与用药前比较,2组患者下肢动脉内膜厚度、斑块和狭窄评分均较治疗前下降(P<0.05);且瑞舒伐他汀组患者内膜厚度、斑块和狭窄评分均低于辛伐他汀组(P<0.05);硬化强度评分治疗前后比较差异无统计学意义(P>0.05)。结论:他汀类药物均可降脂并抗下肢动脉硬化,且瑞舒伐他汀降脂及抗动脉硬化作用优于辛伐他汀。
Objective To observe the clinical effect of rosuvastatin in the treatment of lower extremity atherosclerotic disease in the elderly,and to provide clinical basis of the application of statins in lower extremity atherosclerotic disease in the elderly.Methods 90 patients diagnosed as lower extremity atherosclerotic disease （aged 60 years or over）were randomly divided into simvastatin group and rosuvastatin group （n=45）,and they were treated with simvastatin and rosuvastatin,respectively,based on the regular treatment.The total cholesterol （TC）,low density lipoprotein-cholesterol （LDL-C）, and high sensitivity C-reactive protein （hs-CRP）of the patients in two groups were detected at the begining of treatment and the ending of 32 weeks;at the same time,the lower limb artery intima thickness, strength of hardened, plaque, and artery stenosis degree scores were compared.Results 32 weeks after treatment,the levels of TC,LDL-C and hs-CRP of the patients in two groups were decreased statistically compared with before treatment （P 〈0.05）;the levels of TC,LDC-C,and hs-CRP in rosuvastatin group were lower than those in simvastatin group （P 〈 0.05 ）. 32 weeks after treatment in two groups,compared with before treatment,the lining thickness and plaque,stenosis scores were decreased （P 〈0.05）;the lining thickness,plaque and stenosis scores in rosuvastatin group were lower than those in simvastatin group （P 〈0.05）;the gardening strength grades had no statistical difference between before and after treatment. Conclusion Statins is lipid-lowering and resistant to lower limb arteriosclerosis,and rosuvastatin is better than simvastatin.
出处
《吉林大学学报（医学版）》
CAS
CSCD
北大核心
2015年第6期1260-1263,共4页
Journal of Jilin University：Medicine Edition
基金
吉林省科技厅自然科学基金资助课题(201015145)
